AI-Driven Heart Analysis Revolutionizes Treatment for Heart Disease

2025-03-28 digitalcare

Online, Friday, 28 March 2025.
Cleerly employs AI for non-invasive heart assessments, advancing personalized medicine with better risk evaluation and treatment strategies for heart disease patients.

Revolutionary AI Technology and Recent Funding

Since its founding in 2017, Cleerly has emerged as a frontrunner in AI-driven cardiac care, securing substantial financial backing with $223 million in Series C funding in 2022 and an additional $106 million extension in December 2024 [3]. The company’s breakthrough technology enables comprehensive quantification and characterization of atherosclerosis, utilizing FDA-cleared AI systems for detailed heart image analyses [2]. Operating from offices across Denver, New York, Dallas, and Lisbon, Cleerly has established a global presence in the fight against heart disease [3].

Community Impact and Clinical Implementation

In a significant demonstration of its technology’s practical application, Cleerly recently partnered with Corazon Imaging and Philips at the American College of Cardiology’s Chicago Community Health Fair on March 25, 2025. The event showcased mobile CT scanning capabilities, providing AI-Quantitative Coronary CT analyses directly to community patients [2]. The initiative successfully delivered 14 Cleerly analyses and on-site CCTA scans, marking a substantial step toward democratizing access to advanced cardiac care [5].

Advancing Women’s Cardiovascular Health

The company is set to present groundbreaking research at the ACC.25 conference from March 29-31, 2025, focusing on AI-QCT’s role in predicting major adverse cardiovascular events specifically in women. This international study encompasses 3,500 participants across 11 countries, with approximately half being female [7]. The research represents a significant advancement in understanding gender-specific cardiovascular risks and developing more targeted treatment approaches [7].

Future Trajectory and Healthcare Integration

Cleerly’s commitment to preventing heart attacks is evidenced by its extensive intellectual property portfolio and continuous technological innovation [1]. The company’s Medicare-covered services [2] and partnership with major healthcare providers demonstrate the growing integration of AI-powered cardiac analysis into mainstream medical practice. With its presence at major medical conferences and community health initiatives, Cleerly is actively working to establish a new standard of care in cardiovascular medicine [7].

sources

AI heart disease